Jump Financial LLC Trims Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Jump Financial LLC cut its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 65.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,878 shares of the medical device company's stock after selling 54,296 shares during the quarter. Jump Financial LLC owned 0.06% of AtriCure worth $883,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Blue Trust Inc. increased its position in AtriCure by 1.8% in the 4th quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock valued at $414,000 after buying an additional 265 shares in the last quarter. Invesco Ltd. increased its holdings in shares of AtriCure by 0.8% during the fourth quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock valued at $1,334,000 after acquiring an additional 334 shares in the last quarter. Perkins Capital Management Inc. raised its position in shares of AtriCure by 1.3% during the fourth quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock worth $927,000 after purchasing an additional 400 shares during the period. Truist Financial Corp raised its position in shares of AtriCure by 2.6% during the fourth quarter. Truist Financial Corp now owns 15,717 shares of the medical device company's stock worth $480,000 after purchasing an additional 403 shares during the period. Finally, Franklin Resources Inc. lifted its holdings in shares of AtriCure by 0.9% in the 3rd quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock worth $1,569,000 after purchasing an additional 484 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors.

AtriCure Stock Performance

Shares of ATRC stock traded down $0.35 during trading on Friday, hitting $33.40. The company's stock had a trading volume of 426,193 shares, compared to its average volume of 655,652. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.65 billion, a PE ratio of -35.16 and a beta of 1.65. The business has a fifty day moving average of $34.32 and a 200-day moving average of $34.66. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11.

Insiders Place Their Bets

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now owns 17,828 shares of the company's stock, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on ATRC shares. Stifel Nicolaus boosted their price target on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Canaccord Genuity Group decreased their target price on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. Oppenheimer raised their price target on shares of AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a research note on Thursday, March 27th. Finally, JPMorgan Chase & Co. lowered their price objective on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, March 27th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, AtriCure currently has a consensus rating of "Moderate Buy" and a consensus target price of $49.44.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.